Cargando…
Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
Neurocutaneous melanosis (NCM) is a rare congenital disorder characterized by the association of large and/or multiple congenital melanocytic nevi (CMN) of the skin with melanocytic lesions of the leptomeninges, including melanocytosis. Leptomeningeal melanocytosis carries a poor prognosis once neur...
Autores principales: | Küsters-Vandevelde, Heidi VN, Willemsen, Annelieke ECAB, Groenen, Patricia JTA, Küsters, Benno, Lammens, Martin, Wesseling, Pieter, Djafarihamedani, Melika, Rijntjes, Jos, Delye, Hans, Willemsen, Michel A, van Herpen, Carla ML, Blokx, Willeke AM |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023633/ https://www.ncbi.nlm.nih.gov/pubmed/24713450 http://dx.doi.org/10.1186/2051-5960-2-41 |
Ejemplares similares
-
MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018) -
Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment?
por: van Engen-van Grunsven, Adriana C. H., et al.
Publicado: (2014) -
MEK1 is required for the development of NRAS-driven leukemia
por: Nowacka, Joanna D., et al.
Publicado: (2016) -
RARE-10. Neurocutaneous melanocytosis-associated hydrocephalus: the MSK experience from 2001-2022
por: Rodriguez, Scarlett, et al.
Publicado: (2022) -
Improved discrimination of melanotic schwannoma from melanocytic lesions by combined morphological and GNAQ mutational analysis
por: Küsters-Vandevelde, Heidi V. N., et al.
Publicado: (2010)